Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ De-recognition of operating lease asset on lease assignment / termination

De-recognition of operating lease asset on lease assignment / termination at other companies

Maplebear Inc. logo
Maplebear Inc.CART
$4.25M+1,600%
Schering-Plough logo
Schering-PloughSGP
$732.25K—
Synopsys logo
SynopsysSNPS
$36.41M+38.7%
Deckers Outdoor Corporation logo
Deckers Outdoor CorporationDECK
$86K-88.5%
Toast logo
ToastTOST
$6M—
General Mills logo
General MillsGIS
$25.1M—

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept jazz:DeRecognitionOfOperatingLeaseAssetOnLeaseAssignmentTermination.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's de-recognition of operating lease asset on lease assignment / termination.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's de-recognition of operating lease asset on lease assignment / termination?
Jazz Pharmaceuticals (JAZZ) reported de-recognition of operating lease asset on lease assignment / termination of $585.5K in Q4 2025.
How has Jazz Pharmaceuticals's de-recognition of operating lease asset on lease assignment / termination changed year-over-year?
Jazz Pharmaceuticals's de-recognition of operating lease asset on lease assignment / termination decreased by 88.2% year-over-year, from $4.97M to $585.5K.
What is the long-term trend for Jazz Pharmaceuticals's de-recognition of operating lease asset on lease assignment / termination?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's de-recognition of operating lease asset on lease assignment / termination has grown at a -55.0% compound annual growth rate (CAGR), from $56.97M to $2.34M.
What does de-recognition of operating lease asset on lease assignment / termination mean?
The value of assets removed from the books due to lease termination.
How do you interpret de-recognition of operating lease asset on lease assignment / termination?
High levels of de-recognition may indicate restructuring, consolidation of facilities, or exit from specific geographic locations.
How does de-recognition of operating lease asset on lease assignment / termination compare across companies?
Reflects operational changes; common during corporate restructuring or office consolidation.